V k genes in chronic lymphocytic leukaemia: highly skewed V gene segment usage with similar CDR3 sequences
Expression of a single antibody specificity by normal B cells is essential for the normal functioning of the immune system. Naive B cells express germline, unmutated immunoglobulin genes, but B cells that have encountered an antigen and moved through a germinal centre have antibody genes that bear mutations. Specific antigen-antibody interaction can drive proliferation and potentially this is significant in driving the proliferation of B-cell malignancies including chronic lymphocytic leukaemia (CLL). There is a biased V H gene usage in malignant B-cell populations (particularly CLL 1, 2 ), which supports the importance of antibody-specific processes in driving or maintaining this malignancy. About half of all CLL cases have unmutated immunoglobulin genes and this is associated with poor clinical outcome. One allele of V H 1-69 in CLL is overexpressed in unmutated cases of CLL 3 and the sequence of the CDR3 region, which is important in antigen binding, is identical in a surprisingly high proportion of patients 4, 5 again suggesting that antigen-driven processes may be important in leukaemogenesis. There is much less work on the light-chain V gene usage in CLL but there is a biased usage of both k and l light chains. 6 We have sequenced rearranged V L genes from l expressing cases of CLL. In distinction to the previous work on V l gene usage based on southern European 6 or North American populations, our cases are drawn from northern Europe.
We have PCR amplified (see figure legend) and sequenced rearranged V l gene segments from DNA extracted from B cells purified from peripheral blood. Eighty-one rearrangements were amplified from CLL and the PCR product was cloned and sequenced. Sequences were compared to those of germline V l genes compiled in the IMGT database 7 in order to find the most likely V l gene, J l gene and mutational status.
There was highly preferential usage of certain V l gene segments (Figure 1a ) in CLL. IGL3-21n01 was used in 37% of the cases and IGL2-14n01, IGL2-14n03, IGL3-21n02 and IGL10-54n01 all being used in more than 5% of the rearrangements. The overall usage of IGL3-21 (including both the IGL3-21n01 and IGL3-21n02 alleles) is 44%. Others 6 showed a similar high frequency of IGL3-21n01 at 21%, but did not find any cases expressing IGL3-21n02. However, we also found several V l gene segments (IGL1-41n01, IGL1-47n01, IGL2-14n03 and IGL5-45n03) that had not previously been reported in CLL. There is also over-representation of IGL10-54n01 (6% in this study and 1% in Stamatopoulos et al. 6 ) and underrepresentation of IGL2-8n01 (3 and 14% in Stamatopoulos et al. 6 ). J2n01 and J3n02 were the predominant J l gene segments used in those cases where an assignment could be made. Overall, 32 rearrangements (40%) showed 498% homology to germline sequence and 49 rearrangements (60%) had significant number of mutations. However, among IGL3-21 rearrangements there was a statistically significant excess of unmutated sequences (P ¼ 0.01, Fisher's exact test) compared to all the other V l gene rearrangements.
The CDR3 region can be diversified at both the V(D)J recombination stage, within the bone marrow, and by somatic hypermutation at the germinal centre stage of development. It is, thus, an important contributor to antigen binding specificity. Analysis of CDR3 regions in CLL has demonstrated that unrelated cases can share structural features 8 and has allowed grouping into subsets, some of which showed homology for only light chains . 6 We undertook an analysis of CDR3 regions in our cases ( Figure 1b) . As others have reported, there is a striking similarity between IGL3-21 CDR3 regions in both length (12 amino acids) and sequence. This appears most prominent with Letters to the Editor the predominant J3n02 rearrangements and is observed with both mutated and unmutated cases. Interestingly, although only two cases used J7n02 both have an identical sequence and a length of 10 amino acids. This degree of homology was not seen with J1n01 or J2n01. We did not find sequence homology with IGL2-14n03 (all of which were mutated), but the CDR3 region of IGL10-54n01 rearrangements again showed a high degree of homology, which is likely to represent a novel subset.
In summary, we have carried out an extensive analysis of Vl rearrangements in CLL and demonstrate a highly skewed V gene segment usage. Within this distribution it appears that some Vl genes, but not others, show CDR3 homology and this may be partly independent of mutational status and Jl segment gene usage. Acute myeloid leukemia (AML) is a relentless hematological malignancy characterized by overproduction of hematopoietic precursor cells with impaired differentiation. Increasing evidences suggest that the development of AML is a multistep process that requires collaboration of at least two classes of mutations: class I mutations activate signal-transduction pathway and confer a proliferation advantage to hematopoietic cells, and the class II mutations affect transcription factors and serve primarily to impair hematopoietic differentiation.
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The PTPN11 gene encodes human SHP2, a nonreceptor tyrosine phosphatase on chromosome 12q24, which participates in signal events downstream of the receptors of growth factors and cytokines and plays a key role in the proliferation and survival of hematopoietic cells. Germ line PTPN11 mutations in patients afflicted with Noonan syndrome were first reported by Tartaglia et al. 3 Subsequently, somatic PTPN11 mutations were also found in patients with juvenile myelomonocytic leukemia, myelodysplastic syndrome, childhood AML and acute lymphoblastic leukemia. To the best of our knowledge, however, the characteristics of adult AML with PTPN11 mutation have not been comprehensively studied yet, and the gene alteration that is cooperative with the PTPN11 mutation in the pathogenesis of AML remains largely unknown. In this study, we investigated prevalence and clinical relevance of PTPN11 mutations and their association with other genetic changes from 272 consecutive patients with primary AML. PTPN11 mutations were detected by PCR and direct sequencing using the primers covering exons 3 and 13. 4 Mutational analyses of N-RAS, K-RAS, NPM1, FLT3/ITD, FLT3/TKD, CEBPA, KIT, AML1 and MLL/PTD were performed as previously described. 5, 6 The correlation of genetic mutations with clinical and laboratory characteristics is summarized in Supplementary Table 1. Among the 272 AML patients recruited, 165 were males and 107 were females with a median age of 52.5 years (range, 19-90). Overall, 15 PTPN11 mutations were detected in 
